Compare Mesoblast Limited (MESO) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Xylem, Inc. — how do they compare? Mesoblast Limited trades at $13.76 (market cap $1.83B), while Xylem, Inc. trades at $102.9 (market cap $23.94B). The key difference: Xylem, Inc. is far larger — about 13.1× Mesoblast Limited's market cap, and Xylem, Inc. pays a 1.68% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Xylem, Inc. for 51 Days on average.
| MESO | XYL | |
|---|---|---|
Market Cap | $1.83B | $23.94B |
Volume | 259,445 | 1,097,519 |
Sector | Health | Industrials |
52-Week High | $20.96 | $152.95 |
52-Week Low | $13.19 | $100.92 |
Typical Hold Time | 15 Days | 51 Days |
Enterprise Value | $1.91B | $25.72B |
Dividend Yield | — | 1.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.895, down 2.63% with bearish technical signals. The company reported substantial revenue growth to $120M in 2026 but remains unprofitable with a net margin of -47.82%. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant milestones. The stock shows mixed sentiment with 45% analyst buy ratings against bearish technical indicators.
While MESO demonstrates strong revenue growth potential and pipeline progress, persistent losses and negative profitability metrics present substantial risk. The company's cash position of $161M provides runway, but investors face volatility from clinical trial outcomes and path to profitability challenges.
Xylem (XYL) trades at $102.74, showing modest daily gains of 0.15%. The stock demonstrates strong fundamental performance with consistent earnings beats and revenue growth from $5.5B in 2022 to $9.0B in 2025. Technical indicators signal bearish momentum despite neutral oscillators, with key support at $101. Recent developments include strategic acquisitions of Cornell Pump and Roper Pump, strengthening the company's industrial water solutions portfolio.
Xylem presents a compelling investment case with solid profitability (11.15% net margin) and analyst consensus target of $146.63 offering 43% upside potential. However, technical weakness and China market challenges pose near-term risks. The company's focus on water infrastructure and digital solutions positions it well for long-term growth in essential water technology markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
